RxDoctor Payments Data

Cesar Conde, MD

Cardiovascular Disease · Miami Beach, FLNPI 1932159043

Payments from drug & device makers

$4,088in general payments, 2019–2025

Across 22 payments — averaging $185.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Atricure, Inc.$178
  • Edwards Lifesciences$175
  • Medtronic$102
  • Novartis$70
  • Exact Sciences$46
  • plus $147 from 7 others

What the payments were for

  • Speaking & faculty fees$3,35082%
  • Food & beverage$71818%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,088 in reported general payments places this provider in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$103,837
Medicare patients
2,489
Services billed
4,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$62,744
EntrestoSacubitril/Valsartan20$29,935
Repatha SureclickEvolocumab30$18,525
FarxigaDapagliflozin Propanediol17$17,609
XareltoRivaroxaban13$16,669
Praluent PenAlirocumab11$5,380
VascepaIcosapent Ethyl14$4,744
Rosuvastatin Calcium112$2,739
ClopidogrelClopidogrel Bisulfate65$1,630
Candesartan Cilexetil11$1,458
Amlodipine Besylate89$1,138
Ezetimibe34$1,123
Metoprolol Succinate64$1,032
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide17$914
Valsartan24$833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$70$29,93520 claims
AstraZenecaFarxiga$3,369$17,60917 claims
Johnson & JohnsonXarelto$18$16,66913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →